Hi, I'm Mohamad Mohty from the Sorbonne University and Saint-Antoine Hospital in Paris, in France. And it is my pleasure to be with you, at this ASH 2025, annual meeting in Orlando and discuss, the perspectives when it comes to the relapsed refractory multiple myeloma setting and the greatest advances we've seen in the last a few weeks.
And this is about, in my opinion, the advent of in vivo Car-T cells, but also the use of T-cell engagers bispecific antibodies in the early relapse setting.
So as a kind reminder to all of us, we know that Car-T cells represent a true revolution in the field. It's a single shot treatment. It's about manipulating our own T cells, the T cells of the patient to educate them, to engineer them, to re infuse some and allow the killing of the malignant myeloma plasma cells.
But this process is sophisticated, quite complex. It requires several weeks. So if you're able by just using a drug, giving a drug and all of the processes happening in vivo in the body of the patient, this would be a great advance.
And here at ASH 2025, we've seen the proof of concept. The first data about using such technology and apparently it works. It is safe. It is effective if you look to MRD negativity. So something really brilliant for the future.
We also know that besides Car-T cells, which have shown great efficacy in relapsed multiple myeloma, we have T-cell engagers, lots of, great results in the very advanced heavily pretreated patient. Why not moving them into earlier course of the disease, especially in early relapse? Let's say first or second relapse.
And this is about the results of the majestec-3 trial. Again, another late-breaking abstract at ASH showing that the combination of an antibody, an anti CD38 monoclonal antibody, like daratumumab and teclistamab can lead to dramatic improvement compared to what is currently used to standard of care.
So this is really very exciting. And I think the treatment, recommendations algorithm are likely to change, in the near future if such combination is approved.
But it's not only about bispecific antibodies combined with daratumumab. Now we have excellent data combining two bispecific antibodies, but also even with tri specific antibodies targeting two antigens with one molecule.
So also very promising, data in, very high risk situations like extramedullary disease. But I think the bispecific antibodies are now being also combined with the classical agents like proteasome inhibitors, elranatamab plus carfilzomab or plus pomalidomide.
So you can see now we're trying to use the best off immune therapy and combine it with the other agent. And at the end of the day, the goal is to design and develop the most effective but also the safest, combinations, for a given disease status in a given patient.
So that provides lots of options to patient. And this is really very good news.
Of course we should not forget, the development of antibody drug conjugates like belantamab which are very interesting because, you can likely deliver these agents four, three, four times per year, which is very interesting in terms of quality of life of the patient.
Of course, we need to be aware about the a risk of keratitis, but this is becoming more and more manageable. And this is similar story to what we've seen was bispecific antibodies and opportunistic infections, which can be now mitigated with immunoglobulins and optimal prophylaxis.
So in summary, the treatment algorithm, for relapsed refractory multiple myeloma, is being enriched day after day, especially after this ASH 2025 meeting. And I would say while it appears a bit more complicated on how to choose, I believe it's a very good problem to have and provide more effective options to patients.
HealthTree • December 15, 2025